Panthera Biopartners’ Post

🚨 New report from the The Assistant Secretary for Planning and Evaluation (ASPE) on COVID-19 and clinical trials references IQVIA Institute’s report, Lesson Learned from COVID-19 Vaccine Trials: A CRO perspective on accelerating clinical development. The report explores the impact of the pandemic on clinical trials and highlights key lessons learned. Download it here: https://bit.ly/4dIZ2lD #COVID19 #ClinicalTrials #GlobalHealth

In a groundbreaking collaboration, Walgreens, AstraZeneca, and digital health company Evinova revealed at DPHARM 2024 their initiative to revolutionize patient recruitment for clinical trials. The partnership integrates digital, physical, and community elements to reach patients in Walgreens-served communities, aiming to make clinical trials more accessible. The importance of selecting the right partners and utilizing innovative recruitment strategies was emphasized during the conference session. This collaboration addresses challenges in traditional recruitment methods, bringing clinical trials closer to a diverse and representative patient population. 𝐑𝐞𝐚𝐝 𝐅𝐮𝐥𝐥 𝐀𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/diJifdDz

Trials24 will exhibit at the BIO International Convention 2024 in San Diego, USA We will engage with fellow exhibitors and attendees, sharing insights and exploring collaborations to speed up clinical trials by fast-tracking patient recruitment. The company is particularly looking forward to discussions on several key topics, including: 🔸 Projecting patient recruitment costs: With Trials24’s Patient-Reported Feasibility Studies, we build a recruitment cost model that projects patient enrollment costs by measuring the patient population’s eligibility rate specifically to the study protocol. 🔸 Supporting Global Patient Recruitment: Showing with our case studies from common chronic illnesses to rare diseases how we accelerate patient recruitment by tapping into a patient pool study sites can’t reach.   ➡ We invite all attendees to visit our booth #4315-19 in the German Pavilion and to book a meeting via Partnering Platform with this link: https://lnkd.in/dJQWqMnA or by email at info@trials24.com. Read more in the press release: https://lnkd.in/dB-6FamY #BIOInternationalConvention #PatientRecruitment #ClinicalTrials #FeasibilityStudy #Trials24

At ABPI Industry Summit today is on “building trust in a time of change”. It will be informed by CF work with The Association of the British Pharmaceutical Industry (ABPI) on NHS-industry partnerships and their growing impact on patient care. The UK is unique in the world’s top 10 pharma markets in that it has a specific collaboration framework.  The introduction of a new innovation – including medicine, diagnostic, health tech – is not enough to deliver the potential outcomes and uptake that would maximise benefits to patients. Realising the potential needed a whole system response to enable identification of at risk individuals, diagnosis, initiation of treatment, and ensuring adherence. It turned out to be more challenging to achieve this. #cardiometabolic has been in the news for Eli Lilly and Company and David Riggs, PharmD announcing large investment in obesity—and making the case of the need to consider how the system supports uptake of innovation to improve patient outcomes and economic growth. Whether it is in #CVD, #diabetes, #renal, #obesity there is so much complexity and established habits that changing behaviour requires not just explaining the benefits of innovation but demonstrating how it can be introduced but also supporting the development journey and making sure the formal mechanism are in place. A key challenge is trust: a gulf between industry and the NHS is a lack of intimacy in the “trust equation”. Investment in the relationship but that’s only worth it with mutual shared interest and long term commitment because of the potential impact that can be had. And if there effort is put in to evaluate impact in data-driven way. This report provides evidence of that. Our  research shows collaborations are making a real difference, with data showing significant improvements in prescribing practices and health outcomes. For example, partnering NHS trusts are up to 2.5 times more likely to prescribe cost-effective medicines in line with NICE guidelines, and primary care networks see 28% higher rates of cardiovascular disease control compared to the national average. At today’s #ABPI Industry Summit, I’m looking forward to discussing how we can continue building trust and expanding these partnerships in a time of global change. Let’s keep the momentum going to ensure we deliver better care for patients across the UK. The Association of the British Pharmaceutical Industry (ABPI) NHS NHS England Department of Health and Social Care Medicines and Healthcare products Regulatory Agency Russell Abberley Richard Torbett MBE Brian Duggan Fiona Bride Samantha Roberts NHS Confederation See more about our research in CF's latest snapshot: https://lnkd.in/e5fvksYr

Clinical trials are essential to allow patients access to the latest innovative treatment options, up to 5-10 years before launch! That is one of the key findings of a new study by @IQVIA for @Efpia.    In the report they conclude that while the number of clinical trials is increasing globally, the share of trials performed in #Europe is falling considerably. In actual numbers, this translates to 60,000 fewer patients today accessing a trial involving a country within the European Economic Area, compared to a decade ago.   If #patients in Europe are to have the same opportunities to access medical breakthroughs as patients elsewhere in the world, we need to urgently address this downward trend. This will only be possible if the EU works to harmonize and simplify its #clinicaltrials landscape across the region, making it easier to carry out multi-country trials.    To read more on the findings and recommendations: https://lnkd.in/dpam-2BQ   #healthforall #hungerfornone @Bayer @BayerPharmaceuticals

In case you missed it, our VP of Strategic Operations Marcy Kravet sat down with VCTC's Rosia Shah and PPD's Tom Westgate at #SCOPEsummit Europe for a panel on building greater trust and transparency in clinical trials. Recap the big takeaways and learn more about how site and CRO leaders are reimagining industry collaboration here: https://lnkd.in/d-XUwUM2 

For those focused on patient recruitment, the Phesi Investigator Site Profile offers a valuable tool for enhancing investigator site enrollment performance. This tool provides quantifiable performance scores based on enrollment, site activation, and patient data quality, offering incremental improvements to your existing toolkit. Developed and validated by clients over 18 years, it has supported the development of prominent medications like Keytruda and Kisunla. If boosting site performance is your goal, this could be a game-changer for you. #clinicaltrials #clinicaldevelopment #patientrecruitment #patientenrollment #clinicaloperations

Interesting article on the decline of clinical trials in Europe. My take aways: maybe we should learn from Spain and China and reduce the administrative burden to start clinical trials (it is painful to witness….) Thanks Karin for sharing!

🌟 Exciting News in COPD Treatment! 🌟 Dupilumab (Dupixent®) is known as a fully human monoclonal antibody directly against the interleukin (IL)-4 receptor alpha(IL-4Ralpha); Shirley, M. Dupilumab: First Global Approval. Drugs 77, 1115–1121 (2017). Since the first approval for moderate-to-severe atopic dermatitis in March 2017, it has a notable approval history. 1. March 2017: Dupilumab received its first FDA approval in the United States for treating moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 2. September 2017: The European Medicines Agency (EMA) granted marketing authorization for Dupilumab in the European Union to treat moderate-to-severe atopic dermatitis in adults. 3. October 2018: The FDA expanded Dupilumab's indication to include the treatment of moderate-to-severe asthma in patients aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. 4. June 2019: The FDA approved Dupilumab for treating chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not adequately controlled. 5. May 2020: Dupilumab received FDA approval for treating moderate-to-severe atopic dermatitis in pediatric patients aged 6 to 11 years. 6. May 2022: The FDA approved Dupilumab for treating eosinophilic esophagitis (EoE) in patients aged 12 years and older, making it the first treatment for this condition. 7. September 2022: The FDA approved Dupilumab's indication to include the treatment of prurigo nodularis. In addition, I'm thrilled to share that on July 3, 2024, the European Medicines Agency (EMA) approved Sanofi's Dupixent for treating COPD in adults! 🎉 This authorization marks a significant advancement in the management of COPD, particularly for patients who are on a combination of inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), and long-acting muscarinic antagonist (LAMA), or on LABA and LAMA if ICS is unsuitable. This approval is supported by the robust findings from the Phase III BOREAS and NOTUS studies.🌬️👏 Kudos to the teams involved in those various clinical trials and all the researchers involved in these groundbreaking studies. This is a big win for the medical community and patients alike. 💪🔬 In South Korea, various clinical trials for COPD are currently recruiting subjects. Please keep an eye on all efforts and commitment to treating COPD!! https://lnkd.in/gSRexK5N #COPD #HealthcareInnovation #MedicalBreakthrough #EMAApproval #RespiratoryHealth #ClinicalTrials #CRO #CNRResearch #EMA #Korea #MFDS #임상시험 #씨엔알리서치 #글로벌임상시험 #한국임상시험

In todays EFPIA issue an alarming article about the declining number of clinical trials being conducted in Europe. Very interesting to read!